Clinical Trial Update: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for trametinib in progressive metastatic hormone-resistant prostate cancer; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer
• Prostate Carcinoma

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING